Replimune Group Inc (REPL) Stock Analysis

Replimune Group Inc (REPL) is a publicly traded company in the HEALTHCARE sector. It trades at $8.87, carries a market capitalization of $743.15M. This page summarizes the public market data, fundamentals, and frequently asked questions for REPL, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Replimune Group Inc currently has a Bullish sentiment score of 0.48.

About Replimune Group Inc

Replimune Group, Inc., headquartered in Woburn, Massachusetts, is at the forefront of biotechnology, specializing in the development of oncolytic immunotherapies aimed at revolutionizing cancer treatment. Utilizing its proprietary Immuno-Oncology platform, the company targets cancer cells with precision while enhancing the body's immune response against tumors. Replimune's advancing clinical programs demonstrate the potential effectiveness of its innovative therapies, establishing it as a key...

GNG Research Analysis

GNG Research scores Replimune Group Inc (REPL) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for REPL.

Frequently Asked Questions

Does REPL pay dividends?

Replimune Group Inc (REPL) does not currently pay a regular dividend.

What is REPL's market cap?

Replimune Group Inc (REPL) has a market capitalization of $743.15M with a current stock price of $8.87.